{"title":"罗氏授权Galaxy Biotech的临床前FGF2抗体项目","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I10.1818","DOIUrl":null,"url":null,"abstract":"Roche has licensed global rights to Galaxy Biotech’s preclinical-stage antibodies that target fibroblast growth factor 2 (FGF2), a key target in cancer metastasis. Roche will assume responsibility for the development and commercialisation of the programme and will pay Galaxy US$8 M upfront as well as potential milestone payments and royalties. The deal comes 3 months after Takeda Pharmaceutical terminated its licence agreement with Galaxy for the anti-HGF (hepatocyte growth factor) monoclonal antibody HuL2G7.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"238 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Roche In-Licenses Galaxy Biotech’s Preclinical FGF2 Antibody Programme\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I10.1818\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Roche has licensed global rights to Galaxy Biotech’s preclinical-stage antibodies that target fibroblast growth factor 2 (FGF2), a key target in cancer metastasis. Roche will assume responsibility for the development and commercialisation of the programme and will pay Galaxy US$8 M upfront as well as potential milestone payments and royalties. The deal comes 3 months after Takeda Pharmaceutical terminated its licence agreement with Galaxy for the anti-HGF (hepatocyte growth factor) monoclonal antibody HuL2G7.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"238 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I10.1818\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I10.1818","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Roche has licensed global rights to Galaxy Biotech’s preclinical-stage antibodies that target fibroblast growth factor 2 (FGF2), a key target in cancer metastasis. Roche will assume responsibility for the development and commercialisation of the programme and will pay Galaxy US$8 M upfront as well as potential milestone payments and royalties. The deal comes 3 months after Takeda Pharmaceutical terminated its licence agreement with Galaxy for the anti-HGF (hepatocyte growth factor) monoclonal antibody HuL2G7.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
